Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial-Reference-Cited by-同舟云学术

Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial

Published:2009-11 Issue:11 Volume:11 Page:697-705
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Rosenstock Julio¹,Cefalu William T.²,Hollander Priscilla A.³,Klioze Sol S.⁴,Reis Joann⁴,Duggan William T.⁴

Affiliation:

1. Dallas Diabetes and Endocrine Center, Dallas, Texas.

2. Pennington Biomedical Research Center, Baton Rouge, Louisiana.

3. Baylor University Medical Center, Dallas, Texas.

4. Pfizer Global Research and Development, New London, Connecticut.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2009.0062

Reference29 articles.

1. Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise

2. Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes

3. An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Metformin as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on a Sulfonylurea

4. An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin

5. Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems;Current Drug Delivery;2023-07

2. Mid‐childhood fat mass and airflow limitation at 15 years: The mediating role of insulin resistance and C‐reactive protein;Pediatric Allergy and Immunology;2022-12

3. Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 Diabetes;Endocrine Practice;2021-01

4. Advancements in the co-formulation of biologic therapeutics;Journal of Controlled Release;2020-11

Metabolic Dysfunction and Asthma: Current Perspectives

;Journal of Asthma and Allergy;2020-07